发布求助
文献互助 智能选刊 最新文献

Nature Reviews. Drug Discovery最新文献

筛选
英文 中文
Menin inhibitors seek to debut as newest targeted therapy for leukaemia 梅宁抑制剂有望作为白血病最新靶向疗法首次亮相
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-21 DOI: 10.1038/d41573-024-00106-3
Ken Garber
{"title":"Menin inhibitors seek to debut as newest targeted therapy for leukaemia","authors":"Ken Garber","doi":"10.1038/d41573-024-00106-3","DOIUrl":"10.1038/d41573-024-00106-3","url":null,"abstract":"Small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias. Small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR T cells take to the airways CAR T 细胞进入呼吸道
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-19 DOI: 10.1038/d41573-024-00105-4
Yvonne Bordon
{"title":"CAR T cells take to the airways","authors":"Yvonne Bordon","doi":"10.1038/d41573-024-00105-4","DOIUrl":"10.1038/d41573-024-00105-4","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141427297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular targeted protein degrader removes antibodies in first test in humans 在首次人体试验中，细胞外靶向蛋白降解器清除了抗体。
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-18 DOI: 10.1038/d41573-024-00103-6
Asher Mullard
{"title":"Extracellular targeted protein degrader removes antibodies in first test in humans","authors":"Asher Mullard","doi":"10.1038/d41573-024-00103-6","DOIUrl":"10.1038/d41573-024-00103-6","url":null,"abstract":"Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader. Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition 了解你的分子：候选药物的药理学特征，以提高疗效并减少后期损耗。
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-18 DOI: 10.1038/s41573-024-00958-9
Terry Kenakin
{"title":"Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition","authors":"Terry Kenakin","doi":"10.1038/s41573-024-00958-9","DOIUrl":"10.1038/s41573-024-00958-9","url":null,"abstract":"Despite advances in chemical, computational and biological sciences, the rate of attrition of drug candidates in clinical development is still high. A key point in the small-molecule discovery process that could provide opportunities to help address this challenge is the pharmacological characterization of hit and lead compounds, culminating in the selection of a drug candidate. Deeper characterization is increasingly important, because the ‘quality’ of drug efficacy, at least for G protein-coupled receptors (GPCRs), is now understood to be much more than activation of commonly evaluated pathways such as cAMP signalling, with many more ‘efficacies’ of ligands that could be harnessed therapeutically. Such characterization is being enabled by novel assays to characterize the complex behaviour of GPCRs, such as biased signalling and allosteric modulation, as well as advances in structural biology, such as cryo-electron microscopy. This article discusses key factors in the assessments of the pharmacology of hit and lead compounds in the context of GPCRs as a target class, highlighting opportunities to identify drug candidates with the potential to address limitations of current therapies and to improve the probability of them succeeding in clinical development. Deeper pharmacological characterization of hit and lead compounds is being enabled by novel assays to characterize target behaviour as well as by advances in structural biology. This article discusses key factors in pharmacological characterization in the context of G protein-coupled receptors as a target class, highlighting opportunities to identify drug candidates with the potential to address limitations of current therapies and to increase the probability of them succeeding in clinical trials.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicines 作者更正：二级药理学的最新进展及其对新药安全性的影响。
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-17 DOI: 10.1038/s41573-024-00993-6
Richard J. Brennan, Stephen Jenkinson, Andrew Brown, Annie Delaunois, Bérengère Dumotier, Malar Pannirselvam, Mohan Rao, Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, Yoav Timsit, Vicencia Toledo Sales, Duncan Armstrong, Armando Lagrutta, Scott W. Mittlestadt, Russell Naven, Ravikumar Peri, Sonia Roberts, James M. Vergis, Jean-Pierre Valentin
{"title":"Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicines","authors":"Richard J. Brennan, Stephen Jenkinson, Andrew Brown, Annie Delaunois, Bérengère Dumotier, Malar Pannirselvam, Mohan Rao, Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, Yoav Timsit, Vicencia Toledo Sales, Duncan Armstrong, Armando Lagrutta, Scott W. Mittlestadt, Russell Naven, Ravikumar Peri, Sonia Roberts, James M. Vergis, Jean-Pierre Valentin","doi":"10.1038/s41573-024-00993-6","DOIUrl":"10.1038/s41573-024-00993-6","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41573-024-00993-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA approves first telomerase inhibitor FDA 批准首个端粒酶抑制剂
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-14 DOI: 10.1038/d41573-024-00102-7
Asher Mullard
{"title":"FDA approves first telomerase inhibitor","authors":"Asher Mullard","doi":"10.1038/d41573-024-00102-7","DOIUrl":"10.1038/d41573-024-00102-7","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Upcoming market catalysts in Q3 2024 2024 年第三季度即将出现的市场催化剂
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-12 DOI: 10.1038/d41573-024-00099-z
Kaniaw Dilzer
{"title":"Upcoming market catalysts in Q3 2024","authors":"Kaniaw Dilzer","doi":"10.1038/d41573-024-00099-z","DOIUrl":"10.1038/d41573-024-00099-z","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141309001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments 基于反义和CRISPR的药物为更好地治疗遗传性血管性水肿提供了案例
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-11 DOI: 10.1038/d41573-024-00101-8
Asher Mullard
{"title":"Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments","authors":"Asher Mullard","doi":"10.1038/d41573-024-00101-8","DOIUrl":"10.1038/d41573-024-00101-8","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141304517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chromatin-targeted drug discovery at “a very special moment” 处于 "非常特殊时刻 "的染色质靶向药物发现
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-11 DOI: 10.1038/d41573-024-00096-2
Asher Mullard
{"title":"Chromatin-targeted drug discovery at “a very special moment”","authors":"Asher Mullard","doi":"10.1038/d41573-024-00096-2","DOIUrl":"10.1038/d41573-024-00096-2","url":null,"abstract":"Cigall Kadoch, a cancer researcher at Dana-Farber Cancer Institute and co-founder of Foghorn Therapeutics, discusses the case for a new wave of epigenetic drugs, targeting chromatin remodelling complexes. Cigall Kadoch, a cancer researcher at Dana-Farber Cancer Institute and co-founder of Foghorn Therapeutics, discusses the case for a new wave of epigenetic drugs, targeting chromatin remodelling complexes.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141304382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA delivery heats up cold tumours RNA 输送为寒冷的肿瘤升温
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-06-10 DOI: 10.1038/d41573-024-00098-0
M. Teresa Villanueva
{"title":"RNA delivery heats up cold tumours","authors":"M. Teresa Villanueva","doi":"10.1038/d41573-024-00098-0","DOIUrl":"10.1038/d41573-024-00098-0","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信